Assembly Biosciences maintains a 'Buy' rating due to its advancing drug pipeline and solid cash reserves of $320.4 million, providing financial stability through 2029. Key upcoming catalysts include phase 2 trials for GS-1179 targeting genital herpes and ABI-6250 for chronic HDV, PBC, and PSC, with multiple trial results expected between 2027 and 2028. The company's partnership with Gilead on GS-1179 offers flexible financial benefits, including milestone payments or profit sharing. This strong positioning supports Assembly's clinical development and growth strategy.
An analyst initiates coverage of Sandisk with a BUY rating, highlighting the company's exposure to yen costs through its joint venture with Kioxia Holdings in Japan. Although Sandisk does not own its manufacturing fabs, its high margins and cash flow...
Institutional investors are showing renewed interest in Bitcoin, with analysts suggesting the market bottom may be near. Despite positive sentiment and regulatory moves by the CFTC and SEC, Bitcoin trading volumes have dropped to multi-year lows, lim...
Cardano's Dijkstra upgrade remains on track, with Phase 1 aiming for mainnet deployment by the end of 2026. This phase includes major features like Linear Leios and Nested Transactions to improve scalability and transaction handling. The second phase...
Michael Saylor's new essay claims Bitcoin is a better form of money than gold or fiat currency because it combines their advantages while minimizing weaknesses. He explains that good money must preserve value over time and be transferable across bord...
LandBridge, a major holding in Leo Nelissen's portfolio, is advancing with seven counterparties in late-stage talks for over 10 GW of power and data center projects, expecting revenue by next year-end. The company's produced water business is growing...
